Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome

Image

Cannabis News
October 1, 2024

SciSparc receives FDA approval for a Phase IIb trial of a cannabinoid based treatment for Tourette Syndrome. SciSparc Ltd., a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company

Cannabis Technology News

by Rolando Garcia

Read More: Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome